Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
WOBURN, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today presented two oral presentations highlighting promising clinical data from its RP1 and RP2 programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago.
- “The strength of the RP1 and RP2 data being presented at ASCO in two hard-to-treat tumor types further validates the potential of the RPx platform,” said Sushil Patel, Ph.D., CEO of Replimune.
- Approximately one third of patients experienced a response, with an overall response rate (ORR) by investigator assessment of 32.7%.
- In the 94 patients who had primary resistance to their immediate prior anti-PD-1 therapy, the ORR was 34%.
- Biomarker data indicate immune cell infiltration and increased PD-L1 expression in tumors, together with changes in the systemic T cell repertoire following RP2 plus nivolumab.